HKEX-listed biotechs. Pipeline valuation anchored to observable licensing transactions — not DCF assumptions.
Hong Kong biotech under Chapter 18A created one of the largest pre-profit pharmaceutical listing ecosystems in Asia. Many of these companies now have approved drugs, real revenue, and documented licensing deals with global partners — but they are still priced as pre-revenue speculation. When a comparable transaction (an in-licensing deal, a milestone payment) provides a hard data point on the value of a single asset, the market valuation of the broader pipeline becomes a measurable question, not a modelling exercise.
AstraZeneca Paid US$100M for One Molecule. The Rest Trades at US$507M.
AstraZeneca paid US$100M upfront for one Jacobio molecule still in Phase I, plus up to US$1.9B in milestones. The entire company trades at US$730M. Subtract net cash: the market values everything else — an approved cancer drug, an ongoing Phase III trial, and the milestone pipeline — at US$507M.
← All analyses